Neuralstem, Inc. is a biopharmaceutical company based in Rockville, MD, specializing in the research and development of innovative therapies for nervous system diseases. Utilizing their neural stem cell technology, the company is focused on advancing treatments for major depressive disorder, Angelman syndrome, cognitive impairment, neuropathy associated with diabetes, stroke, and other related conditions.
With a robust pipeline of clinical programs, Neuralstem is actively developing both small molecule and stem cell therapy approaches. Their lead asset, NSI-189, is currently in clinical development for major depressive disorder and in preclinical development for various indications. Committed to advancing their research, Neuralstem seeks partnerships and collaborations to support their programs and drive innovation in nervous system therapies.
Generated from the website